1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
Real-time Euronext Paris  -  10:01 2022-08-15 am EDT
2.255 EUR   +1.58%
07/20Corteva, 2Blades Reach Milestone to Develop Transgene for Asian Soybean Rust
MT
06/28Merck & Co. to Supply Keytruda Drug for Transgene, BioInvent's Clinical Study in Solid Tumors
MT
06/28Transgene and Bioinvent Announces Clinical Trial Collaboration and Supply Agreement with Msd to Evaluate Bt-001 in Combination with Keytruda®
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Merck & Co. to Supply Keytruda Drug for Transgene, BioInvent's Clinical Study in Solid Tumors

06/28/2022 | 03:06am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOINVENT INTERNATIONAL AB (PUBL) 2.34% 48.1 Delayed Quote.1.73%
MERCK & CO., INC. -0.46% 90.6 Delayed Quote.18.22%
TRANSGENE 1.58% 2.255 Real-time Quote.-11.22%
All news about TRANSGENE
07/20Corteva, 2Blades Reach Milestone to Develop Transgene for Asian Soybean Rust
MT
06/28Merck & Co. to Supply Keytruda Drug for Transgene, BioInvent's Clinical Study in Solid ..
MT
06/28Transgene and Bioinvent Announces Clinical Trial Collaboration and Supply Agreement wit..
CI
06/27TRANSGENE : Presentation
PU
06/27Transgene SA and BioInvent International AB Announce Positive Progress for BT-001
CI
06/15TRANSGENE : Virus Powered Immunotherapies against Solid Tumors
PU
06/06Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022
CI
05/27Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials..
CI
05/25Transgene SA Approves Board and Committee Changes
CI
05/25TRANSGENE : Proxy Statments
CO
More news
Financials
Sales 2022 7,90 M 8,04 M 8,04 M
Net income 2022 -32,6 M -33,2 M -33,2 M
Net cash 2022 39,1 M 39,8 M 39,8 M
P/E ratio 2022 -6,83x
Yield 2022 -
Capitalization 224 M 228 M 228 M
EV / Sales 2022 23,4x
EV / Sales 2023 10,8x
Nbr of Employees 143
Free-Float 46,5%
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,26 €
Average target price 3,95 €
Spread / Average Target 75,2%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Alessandro Riva Non-Executive Chairman
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE-11.22%228
GILEAD SCIENCES, INC.-8.81%78 912
VERTEX PHARMACEUTICALS39.13%75 532
REGENERON PHARMACEUTICALS, INC.1.86%67 214
WUXI APPTEC CO., LTD.-20.33%40 830
BIONTECH SE-36.97%38 968